The Most Important Insurance Conversation Life Sciences Service Providers Aren’t Having

For life sciences service providers — organizations whose core business is performing a service rather than owning a product — the dominant exposure is not product liability. It is professional liability: The errors and omissions (E&O) exposure created when a service delivery failure causes financial loss for a client or downstream party. Professional liability insurance for life sciences service providers reflects this reality — and for many service providers, the difference between professional liability and product liability coverage can determine whether a claim is covered.

Why the industry defaults to the wrong coverage

The life sciences insurance market evolved to serve pharmaceutical and biotech innovators. As service provider businesses scaled alongside that ecosystem, insurers and brokers largely applied the same framework. The logic seemed reasonable: These companies touch products; therefore, they need product liability coverage.

The problem is that the logic is only partially right. When a contract manufacturing organization (CMO) makes a compound to exact client specifications and an error occurs, the brand owner carries the primary product liability. The CMO’s exposure is not only the contingent product liability associated with the product injuring the final product user, but also the financial loss its error caused to its client — what the industry calls professional liability for third-party financial loss.

How insurers have responded — and why it hasn’t worked

Some underwriters have responded by adding a lower coverage limit within the product liability policy. This approach has two problems.

First, the limit is often inadequate. A batch failure or clinical trial disruption can generate third-party financial losses in the millions of dollars — one reason clinical trial site insurance deserves its own dedicated review rather than a sublimit buried in a broader policy.

Second, the exclusionary language within these coverages is frequently so restrictive that coverage is difficult to access when a claim arises. Brokers who have not reviewed that language in detail — and most have not — don’t know this until a claim is denied.

The contractual dimension

The underinsurance problem is compounded by the contracts service providers routinely sign. Master service agreements and quality agreements in the life sciences sector frequently include indemnification provisions that transfer significant risk to the service provider — often without a corresponding review of what those obligations mean for their insurance program.

Organizations that align their insurance program with their contractual obligations are significantly better positioned when a claim arises. Having a life sciences insurance broker review contracts alongside legal counsel is a step that can reduce exposure — and one most service providers have not taken.

The private equity effect

Consolidation in the life sciences services sector has accelerated significantly. Private equity (PE) firms have recognized that contract manufacturing, contract research organization (CRO) services and laboratory infrastructure represent scalable businesses with strong demand from the broader pharmaceutical and biotech ecosystem.

Mergers and acquisitions create a distinct set of insurance needs that are less well-recognized in life sciences, including the following:

• Historical tail coverage for acquired entities with prior claims exposure.
• Representations and warranties (R&W) insurance for transactions involving businesses with complex risk profiles.
• Program consolidation across portfolio companies without inadvertently narrowing coverage.
• Management liability for PE-backed leadership teams navigating regulatory scrutiny.

What a properly structured program looks like

Building an insurance program for a life sciences service provider starts from a different premise: E&O and professional liability for third-party financial loss is the primary coverage, not an afterthought. From there, a properly structured program adds contingent product liability insurance structured around the service provider’s role in the product lifecycle, coverage tailored to the specific service type — CMO insurance, CRO insurance, contract development and manufacturing organization (CDMO), laboratory services or clinical site management — and contract review as part of the placement process, not separate from it.

Service providers also benefit from specialized property coverage that reflects the realities of their operations — cleanrooms, sterile manufacturing environments, research animals and high-value analytical equipment with long replacement lead times. These are not standard commercial property risks and require a program tailored to address them.

This approach requires a life sciences insurance broker with sector depth — one who has built programs for CMO and CDMO insurance clients before and can have a credible conversation with underwriters about how these risks are structured.

Moving the conversation forward

Life sciences service providers are essential to how new therapies reach the people who need them. That role deserves an insurance program built to match it — structured around the exposures that matter, with limits that reflect the real financial stakes and language that stands scrutiny when a claim is made.

The right conversation isn’t about whether you have product liability coverage. It’s about whether your professional liability insurance for life sciences is structured correctly, whether your insurance program aligns with your contractual obligations and whether your broker has read the exclusion language in your current policy.

If you’re unsure about how strong you are on these aspects of risk, it’s worth assessing where you stand.

Connect with HUB’s Life Sciences practice to build risk strategies that are as precise as the services you deliver.